Imatinib mesylate responsiveness in aggressive systemic mastocytosis: Novel association with a platelet derived growth factor receptor beta mutation

American Journal of Hematology

Volumn 82, Issue 1, 2007, Pages 77-79

  Dalal, Bakul I ^a   Horsman, Douglas E ^b   Bruyèrè, Hélène ^a   Forrest, Donna L ^c  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c Leukemia Bone Marrow Transplant Program of British Columbia   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; CLADRIBINE; IMATINIB; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PREDNISONE;

ADULT; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL EXAMINATION; CYTOGENETICS; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LOW DRUG DOSE; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; SYSTEMIC MASTOCYTOSIS; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; GENE REARRANGEMENT; HUMANS; MALE; MASTOCYTOSIS, SYSTEMIC; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; REMISSION INDUCTION; TUMOR BURDEN;

EID: 33845941854     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.20833     Document Type: Article

References (4)

1. Lydon NB, Druker BJ. Lessons learned from the development of imatinib. Leukemia Res 2004;28S1:S29-S38.
2. Apperley JF, Gardembas M, Melo JV, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002;347: 481-487.
3. Pardanani A, Elliott M, Reeder T, et al. Imatinib for systemic mast-cell disease. Lancet 2003;362:535-536.
4. Pardanani A, Ketterling RP, Brockman SR, et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood 2003;102:3093-3096.